South Korean crypto exchange Upbit will start trading CT token in three markets—CT/KRW, CT/BTC, and CT/USDT—on October 19 at 6 p.m. local time. This move offers traders options to trade CT against the local currency won, Bitcoin, and Tether, providing flexibility and broader access. The launch marks an important step in expanding CT’s market presence on a major exchange. Trading begins at 5 a.m. ET (09:00 UTC) on the scheduled date.
The Upbit listing of CT token in KRW, BTC, and USDT markets provides context for cryptocurrency trading activity. For readers following the crypto market, here is Pluang's snapshot as of Oct 19, 2026 14:01 WIB: out of 50 major cryptocurrencies priced on Pluang, 36 rose and 13 fell today. Notable moves include EOS at Rp12.649 with an 8.13% gain and a typical hold time of 87 days, SAND at Rp1.088 down 5.55% with a 35% sell to 65% buy order split, and CRV at Rp6.405 up 5.50% with a 43% sell to 57% buy order split and a 62-day typical hold time.
Jyske Bank has repurchased shares valued at approximately DKK 2.15 billion as part of its ongoing share buyback program running from February 2026 to January 2027. The bank has acquired a total of 2,235,959 treasury shares, representing 3.84% of its ...
Jyske Bank is conducting a share buyback program from February 5, 2026, to January 29, 2027, with a maximum value of DKK 3 billion. As of mid-October 2026, the bank has repurchased shares worth approximately DKK 2.15 billion at an average price of DK...
Oculis Holding AG has completed patient randomization in its PREDICT-1 clinical trial testing Licaminlimab, a precision medicine targeting TNFR1-mediated dry eye disease (DED). Two-thirds of the 176 enrolled patients carry a genetic variant linked to...
Ekalia, a joint venture between IBA and Framatome, has signed a collaboration agreement with Telix Pharmaceuticals to accelerate the production of astatine-211 in the United States. Astatine-211 is a promising alpha-emitting radioisotope used in targ...
At ESMO 2026, Roche presented key Phase III trial results showcasing significant advances in cancer treatment. Divarasib demonstrated superior efficacy over first-generation KRAS G12C inhibitors in advanced lung cancer, potentially setting a new stan...
